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Background: Low-dose aspirin is recommended to reduce the risk of cardiovascular disease. However, the questions
with regard to primary prevention have been raised among patients with diabetes. We evaluated low-dose aspirin use
for preventing ischemic stroke in patients with diabetes using a national health insurance database.
Methods: Using data from the Korean Health Insurance Review and Assessment Service database from January 1, 2005,
through December 31, 2009, a population-based retrospective cohort study was conducted with incident patients with
diabetes aged 40 to 99 years old with the initial use of low-dose aspirin during the index period from January 1,
2006 to December 31, 2007. We matched each low-dose aspirin user to one non-user using a propensity score.
The Cox proportional hazards model was used to compare the risk of hospitalization for ischemic stroke in users
and nonusers of low-dose aspirin until December 31, 2009.
Results: Out of 261,065 incident patients with diabetes, 15,849 (6.2%) were low-dose aspirin users. Compared to
non-users, the adjusted hazard ratio (95% confidence interval) of low-dose aspirin users for hospitalization due to
ischemic stroke was 1.73 (95% CI; 1.41-2.12). In a sensitivity analysis of study subjects with more than 1 year
follow-up periods, slightly higher adjusted hazard ratio (1.97, 95% CI; 1.51-2.62) was observed. In the subgroup
analyses, there were no significant changes in the risk of hospitalization for ischemic stroke irrespective of gender,
age, or comorbidity.
Conclusions: In this study of patients with diabetes, the use of low-dose aspirin showed an increased risk of
hospitalization for ischemic stroke. These results suggest that low-dose aspirin use for the primary prevention of
ischemic stroke should be reconsidered in patients with diabetes.
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Low-dose aspirin is recommended to prevent cardiovascu-
lar morbidity and mortality in high risk patients with myo-
cardial infarction or ischemic stroke for the purpose of
secondary prevention. It is also recommended to prevent
cardiovascular events in the adult general population with-
out a previous history of cardiovascular disease [1].* Correspondence: bjpark@snu.ac.kr
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raised doubt about the effectiveness of aspirin in diabetes
patients [2]. Two subsequent randomized controlled trials
that enrolled only patients with diabetes did not show a
benefit of low-dose aspirin in primary prevention for car-
diovascular disease, but did report an increased risk of
gastrointestinal bleeding [3,4]. A meta-analysis by the Anti-
thrombotic Trialists’ Collaboration provided subgroup ana-
lyses including patients with diabetes and found that the
effects of low-dose aspirin on major vascular events were
not statistically significant [5]. Furthermore, another meta-
analysis including diabetic patients without cardiovascularis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cardiovascular events with low-dose aspirin [6]. However,
the previous studies were not sufficient to identify the ef-
fect of primary prevention due to their small sample size,
no information on the use of statins, low level of compli-
ance to aspirin therapy, switching aspirin use status during
follow-up, or lack of precision of outcome measures
[2-4,6]. Based on the limited evidence available, recent
guidelines for managing diabetes mellitus narrow down the
target of low-dose aspirin use for primary prevention to in-
clude only men aged over 50 years and women aged over
60 years, with an additional risk factor [7]. However, ques-
tions have been constantly raised about the use of low-
dose aspirin on primary prevention of cardiovascular
disease among patients with diabetes. Well-designed
real world studies could be help to provide evidence de-
termining the treatment effect with assessing the im-
pact of age, gender or comorbidity. We attempted to
evaluate the risk of ischemic stroke preferentially, be-
cause incidence rate for ischemic stroke was greater
than any other cardiovascular diseases among patients
with diabetes [8]. The objectives of this study were to
evaluate the preventive effects of low-dose aspirin for
ischemic stroke among the incident patients with dia-
betes compared with non-users.
Methods
Ethical approval
This study was approved by the Institutional Review
Board of the National Evidence-based Collaboration
Agency (NECA IRB09-011-2).
Study design and data source
A retrospective cohort study design was used to evaluate
low-dose aspirin use for preventing ischemic stroke in
patients with diabetes.
This study was conducted using the Health Insur-
ance Review and Assessment Service (HIRA) database.
The HIRA database includes all information onFigure 1 Schematic description of the study period.approximately 50 million people, whole Korean popu-
lation covered by the National Health Insurance (NHI)
program since 2000. Every resident in South Korea is
provided with a unique civil registration number.
After with the NHI program provides coverage for all
residents with the form of compulsory social insur-
ance, which ensured the complete follow-up of study
participants. We obtained claims data for patients that
had been submitted by healthcare providers between
January 1, 2005 and December 31, 2009 with anon-
ymized identifiers given by HIRA to protect privacy,
according to the Act on the Protection of Personal In-
formation Maintained by Public Agencies. The data-
base contains information on demographic records,
diagnosis, procedures performed, and prescriptions.
Demographic information included age, gender, and
national health insurance type. The health insurance
type was composed of two parts, health insurance
based on employment or residential area and a separ-
ate program for the lower-income Medicaid group,
which covered 3-5% of the whole population [9]. All
diagnoses were coded using the Korean Classification
of Disease, fifth edition (KCD-5) modification of the
International Classification of Disease and Related
Health Problems, 10th revision (ICD-10). Procedures
were entered into the database based on the HIRA
coding system. The prescription data included the
brand name and generic name of the drug according
to the HIRA drug formulary code, prescription date,
and duration.Study population and exposure measure
The study cohort consisted of incident diabetes patients
during the index period (January 1, 2006 to December
31, 2007), at 40 to 99 years of age at cohort entry
(Figure 1). A patient with diabetes was defined as a pa-
tient diagnosed with diabetes (ICD-10, E10-14) and who
had received a prescription for anti-diabetic medication(s)
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during the index period from January 1, 2006 to December
31, 2007. Because diabetes itself was regarded as a major
risk factor for cardiovascular disease, we included incident
patients with diabetes. To identify incident patients with
diabetes, study participants were excluded if they had any
claims of diabetes during the one year (January 1, 2005 to
December 31, 2005) preceding the start of the index
period. The study population was classified as low-dose
aspirin (75–162 mg/day) users or non-users. The use of
low dose aspirin was identified from the claims during
the index period. The index date was defined as the
date of low-dose aspirin initiation in low-dose aspirin
users, and randomly chosen date among physician visit
dates during the index period in non-users [10].
Patients were excluded from the study i) if they had a
prescription of aspirin as an analgesic agent during the
study period (January 1, 2005 to December 31, 2009), or
ii) received low-dose aspirin before the index period, or
iii) had already recorded ischemic heart disease (I20-25)
or ischemic stroke (I63) or had been prescribed anti-
thrombotic drugs (abcximab, argatroban, bemiparin,
beraprost, cilostazol, clopidogrel, dalteparin, dipyridamole,
enoxaparin, fondaparinux, heparin, iloprost, indobu-
fen, lepirudin, limaprost, mesoglycan, nadroparin, oza-
grel, reviparin, parnaparin, RH-tissue type plasminogen
activator, sarpogrelate, streptokinase, sulodexide, sulfomu-
copolysaccharide, tirofiban, treprostinil, tenecteplase,
ticlopidine, triflusal, urokinase, or warfarin; all the
anti-thrombotic drugs covered by the HIRA during
the study period) before the index period.
Study outcome
The study outcomes of interest were defined as the princi-
pal and subsidiary diagnosis of hospitalization for ischemic
stroke (I63).
Follow-up
A patient was considered to be continuously exposed to
low-dose aspirin if he or she filled a prescription within
the end date of the previous prescription plus 1.5 times
the prescription days’ supply [11]. Of the non-users, sur-
vival time was censored for those who initiated low-dose
aspirin during the follow-up period (January 1, 2006 to
December 31, 2009). All patients were followed until they
experienced an ischemic stroke, initiation of aspirin in
non-users, death, or until the end of the follow-up period
(December 31, 2009), whichever came first. Date of death
was identified by the ICD-10 codes (R96, R98, R99, and
I46.1) that indicate patient death in the claims database.
Statistical analyses
Baseline characteristics were presented as numbers with
percentages for categorical variables and as means withstandard deviations for continuous variables. We ana-
lyzed the patient characteristics including gender, age,
insurance type, diabetes-related factors, co-morbidities,
and use of medications in the year before the index date.
The insurance type was classified as health insurance, Me-
dicaid, or switching between the two groups. Diabetes-
related factors included the type of diabetes and whether
oral hypoglycemic agents or insulin was being used to con-
trol the diabetes. We defined type 1 diabetes-only patients
as those who were recorded as having the ICD-10 code
E10, or else classified as type 2 diabetes patients. Comor-
bidities were identified by ICD-10 codes for each patient,
including essential hypertension (I10), and dyslipidemia
(E78). Potential confounding factors were the use of statins,
angiotensin converting enzyme inhibitors (ACEI), angioten-
sin receptor blockers (ARB), calcium channel blockers
(CCB), beta blockers (BB), thiazide diuretics, and non-
steroidal anti-inflammatory drugs (NSAIDs).
To reduce the effect of confounding by indication, we
matched each low-dose aspirin user to one non-user on
the basis of the propensity score, which was quantified
as the likelihood of receiving low-dose aspirin in the year
before the index date by multivariate logistic regression
analysis [12]. In the model, the use of low-dose aspirin
was used as a dependent variable, and all measured base-
line patient characteristics as listed above were included in
the analysis. We also tested the following clinically plaus-
ible interaction terms: age and co-morbidities, age and use
of medications, as well as co-morbidities and use of medi-
cations. After calculating the predicted probabilities, we
matched each low-dose aspirin user to one non-user using
the Greedy 5-to-1 digit-matching algorithm [13]. Balances
in the distribution of baseline covariates were estimated
by the standardized difference between the two groups,
before and after matching.
We performed a Cox proportional hazard analysis to
evaluate the effects of low-dose aspirin on the incidence
of ischemic stroke after adjusting for use of statins,
ACEI, ARB, CCB, BB, thiazide diuretics, and NSAIDs
during follow-up. The insurance type and anti-diabetic
medications were adjusted since the unbalanced distri-
bution was observed after propensity score matching.
Hazard ratios and their 95% confidence intervals were
calculated. The proportional hazard assumption was
checked by examining the log-log plots of the hazard
functions for each group. Subgroup analyses were con-
ducted to explore the impact of each gender (male, fe-
male), age group (40–69, 70–99), type of diabetes (type
1 only, type2 and others), and presence of essential
hypertension, dyslipidemia. To deal with confounding
by indication, we also examined risk of hospitalization
for ischemic stroke was associated with use of low-dose
aspirin among study subjects with more than 1 year
follow-up periods.
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(version 9.1, SAS Institute, Inc., Cary, NC, USA).
Results and discussion
From the HIRA database, 4,391,065 patients aged 40 to
99 years were diagnosed with diabetes between January
1, 2005 and December 31, 2009. Of these, we identified
569,950 incident patients with diabetes. After applying
exclusion criteria, 261,065 patients were included in the
initial cohort (6.2%) of whom were low-dose aspirin
users and 93.8% of whom were aspirin non-users) and
after matching by propensity score, 15,849 patients
remained in each group (Figure 2).
The baseline characteristics of the study population be-
fore and after matching are presented in Table 1. Before
propensity score matching, the users and the non-users
widely differed on a number of baseline characteristics.
Among the initial cohort, the low-dose aspirin users were
more likely to be older, to have essential hypertension
(48.9% vs. 23.1%) and dyslipidemia (26.3% vs. 11.3%), and
to use of medication: statins (26.5% vs. 11.7%), ACEI
(13.8% vs. 4.9%), ARB (26.7% vs. 10.0%), CCB (39.0% vs.
19.3%), BB (16.7% vs. 10.8%), and thiazide diuretics (27.7%
vs. 12.6%). However, propensity score matched groups
were balanced for gender, age group, type of diabetes,
diagnosis of essential hypertension and dyslipidemia, and
use of medications considered. Standardized differences in
patient characteristics, which were below 0.1 across the
groups, demonstrate substantial improvement in the
balance of covariates [14].
Table 2 shows the incidence rates and risk of ischemic
stroke associated with the use of low-dose aspirin in the
propensity score matched cohort. Of the low-dose as-
pirin users, 340 (2.15%) patients had an ischemic strokeFigure 2 Selection of the study participants from the Health Insuranccompared with 158 (1.00%) in the matched aspirin non-
users. The overall ischemic stroke rate was 5.4 per 1,000
person-years for aspirin users and 3.2 per 1,000 person-
years for aspirin non-users. Using a Cox proportional
hazards model, compared to aspirin non-users, the ad-
justed hazard ratio of aspirin users for hospitalization
for ischemic stroke was 1.73 (95% confidence interval;
1.41-2.12).
We did not find any changes in risk related to gender,
age group, and presence of hypertension, dyslipidemia
from the results of subgroup analyses. Although point esti-
mate for the risk was relatively low in female patients, the
use of low-dose aspirin showed an increased risk of ische-
mic stroke in male patients (aHR 1.93, 95% CI; 1.46-2.55)
or in female patients (aHR 1.52, 95% CI; 1.13-2.15). In the
type of diabetes, type 1 only group was not statistically sig-
nificant (aHR 1.82, 95% CI; 0.90-3.68). Use of aspirin in-
creased the risk of hospitalization for an ischemic stroke
regardless of the presence of comorbidities. The HRs for
the patients with hypertension, without hypertension, with
dyslipidemia, or without dyslipidemia were 1.69 (95% CI;
1.30-2.20), 1.81 (95% CI; 1.32-2.51), 1.68 (95% CI; 1.09-
2.57), or 1.75 (95% CI; 1.39-2.21), respectively.
In a sensitivity analysis of study subjects with more
than 1 year follow-up periods, we found slightly higher
aHR (1.97, 95% CI; 1.51-2.62). The aHR for ischemic
stroke was 3.25 (95% CI; 2.28-4.63) among males and
1.72 (95% CI; 1.16-2.57) among females. The association
between the use of aspirin and the risk of hospitalization
due to ischemic stroke maintained irrespective of gender,
age, or comorbidities (Table 3).
This retrospective cohort study showed that there was in-
creased the risk of low-dose aspirin use for hospitalization
due to ischemic stroke among incident diabetic patientse Review and Sssessment Service database.
Table 1 Baseline characteristics of study cohort by use of low-dose aspirin before and after propensity score matching





d† Aspirin non-user Low-dose aspirin user d†
(N = 244,882) (N = 16,183) (N = 15,849) (N = 15,849)
N (%) N (%) N (%) N (%)
Gender Male 144,933 (59.2) 9,192 (56.8) 0.0483 8,877 (56.0) 8,986 (56.7) 0.0139
Female 99,949 (40.8) 6,991 (43.2) 6,972 (44.0) 6,863 (43.3)
Age 40-49 73,569 (30.0) 3,806 (23.5) 0.3481 3,631 (22.9) 3,737 (23.6) 0.0158
50-59 76,267 (31.1) 5,165 (31.9) 0.0356 4,690 (29.6) 5,067 (32.0) 0.0516
60-69 57,709 (23.6) 4,433 (27.4) 0.1971 4,489 (28.3 4,342 (27.4) 0.0207
70-99 37,337 (15.2) 2,779 (17.2) 0.1385 3,039 (19.2) 2,703 (17.1) 0.0551
Insurance type Health insurance 225,785 (92.2) 14,896 (92.0) 0.0212 14,032 (88.5) 14,615 (92.2) 0.1250
Medicaid 15,399 (6.3) 947 (5.9) 0.0779 1,334 (8.4) 920 (5.8) 0.1018
Switching 3,698 (1.5) 340 (2.1) 0.3086 483 (3.0) 314 (2.0) 0.0681
Type of diabetes Type 1 only 10,505 (4.3) 910 (5.6) 0.0615 1,011 (6.4) 809 (5.1) 0.0548
Type 2 and others 234,377 (95.7) 15,273 (94.4) 14,838 (93.6) 15,040 (94.9)
Antidiabetic medication OHA 206,194 (84.2) 14,315 (88.5) 0.1241 13,078 (82.5) 14,101 (89.0) 0.1854
OHA + insulin 38,688 (15.8) 1,868 (11.5) 2,771 (17.5) 1,748 (11.0)
Diagnosis of essential hypertension Yes 56,688 (23.1) 7,912 (48.9) 0.5566 8,379 (52.9) 7,624 (48.1) 0.0954
Diagnosis of dyslipidemia Yes 27,592 (11.3) 4,253 (26.3) 0.3918 4,601 (29.0) 4,072 (25.7) 0.0749
Medication use Statins 28,601 (11.7) 4,283 (26.5) 0.3832 4,291 (27.1) 4,076 (25.7) 0.0308
ACEI 11,878 (4.9) 2,266 (13.8) 0.3102 2,194 (13.8) 2,028 (12.8) 0.0308
ARB 24,597 (10.0) 4,321 (26.7) 0.4404 4,301 (27.1) 4,063 (25.6) 0.0341
CCB 47,268 (19.3) 6,311 (39.0) 0.4439 6,552 (41.3 6,099 (38.5) 0.0584
Beta blockers 26,413 (10.8) 2,696 (16.7) 0.1713 3,291 (20.8) 2,624 (16.6) 0.1082
Thiazide diuretics 30,824 (12.6) 4,481 (27.7) 0.3834 4,811 (30.4) 4,264 (26.9) 0.0764
NSAID 145,733 (59.5) 10,155 (62.8) 0.0665 10,416 (65.7) 9,939 (62.7) 0.0628
d: standardized difference.
ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; NSAID: non-steroidal anti-inflammatory drugs;
OHA: oral hypoglycemic agents SD: standard deviation.
*Baseline characteristics for study subjects were identified within one year before index date.
†Standardized difference (d) of greater than 0.1 represents meaningful imbalance between study groups.
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world setting. Moreover, we did not observe any differences
in risk related to gender, age group, or presence of hyper-
tension, or dyslipidemia in subgroup analyses and in a sen-
sitivity analysis of study subjects with more than 1 year
follow-up periods. These results suggest that the low-dose
aspirin use for the primary prevention of ischemic stroke is
unnecessary for patients with diabetes.
Contrary to our initial hypothesis, we found that use of
low-dose aspirin increased the risk of hospitalization for
ischemic stroke. Diabetes itself might be contributed to re-
duction of the effectiveness of aspirin due to accelerate
platelet turnover [15-18]. Recently, De Berardis et al. re-
ported that the use of aspirin was not associated with
greater risk of major bleeding among patients with dia-
betes [19]. In this respect, the effect of aspirin in patients
with diabetes was insufficient not only for preventingcardiovascular events but also for increasing the risk of
bleeding. A higher dosing strategy has been proposed by
some to overcome these changes in patients with diabetes
based on the significant results of the Early Treatment of
Diabetic Retinopathy Study trial (650 mg/day) [20]. Henry
et al. suggested that repeated low-dose aspirin use daily in-
stead of higher dosing strategy to improve clinical efficacy
on patients with aspirin resistance [21]. We did not deter-
mine the effect of aspirin dosing due to restricting expos-
ure to low-dose aspirin as current guidelines. Additional
research is required to assess the effect of dose escalation
for resolving aspirin resistance and the occurrence of ad-
verse events in diabetic patients.
Our findings on the effects of ischemic stroke in diabetic
patients correspond to the results of previous observa-
tional studies [22,23]. Leung et al. [22] conducted a longi-
tudinal observational study to examine the benefit and
Table 2 Incidence rates and risk of ischemic stroke associated with use of low-dose aspirin among patients with
diabetes


















Whole matched cohort 158 48,725 3.2 340 44,592 5.4 1.64 (1.32-1.98) 1.73 (1.41-2.12)
Gender Male 81 27,565 2.9 137 25,224 5.4 1.86 (1.56-2.23) 1.93 (1.46-2.55)
Female 77 21,160 3.6 103 19,368 5.3 1.45 (1.08-1.95) 1.52 (1.13-2.15)
Age 40-69 85 39,758 2.1 136 37,060 3.7 1.69 (1.28-2.22) 1.81 (1.37-2.38)





14 3,078 4.5 19 2,287 8.3 1.74 (0.87-3.47) 1.82 (0.90-3.68)
Type 2
and others




Yes 97 24,791 3.9 135 21,306 6.3 1.59 (1.23-2.07) 1.69 (1.30-2.20)
No 61 23,934 2.5 105 23,286 4.5 1.70 (1.24-2.33) 1.81 (1.32-2.51)
Diabetes with
dyslipidemia
Yes 39 13,501 2.9 48 11,255 4.3 1.44 (0.94-2.14) 1.68 (1.09-2.57)
No 119 35,224 3.4 192 33,337 5.8 1.65 (1.31-2.08) 1.75 (1.39-2.21)
CI: confidence interval.
*Adjusted Hazard Ratio calculated using Cox proportional hazard model adjusting for insurance type, anti-diabetic medications at baseline, use of statins, angiotensin
converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics during follow-up.
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2 diabetic patients. In a total of 5 731 patients, the use of
aspirin was associated with increased risk of cardiovascu-
lar diseases and mortality in primary prevention (HR 2.07,
95% CI; 1.66-2.59) during the five-year follow-up. InTable 3 Sensitivity analysis for incidence rates and risk of isc









Whole matched cohort 84 48,553 1.7 139
Gender Male 42 27,476 1.5 78
Female 42 21,077 2.0 61
Age 40-69 48 39,633 1.2 85
70-99 36 8,921 4.0 54
Type of diabetes Type 1
only








Yes 48 24,669 1.9 82
No 36 23,885 1.5 57
Diabetes with
dyslipidemia
Yes 24 13,444 1.8 27
No 60 35,109 1.7 112
CI: confidence interval.*Adjusted Hazard Ratio calculated using Cox proportional haza
of statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beaddition, the study showed that the risk of gastrointestinal
bleeding in aspirin users was rather high. A Swedish rec-
ord linkage study [23] was performed to evaluate the ef-
fect of aspirin on mortality and serious bleeding in
diabetic patients with and without cardiovascular diseases.hemic stroke associated with use of low-dose aspirin











44,527 3.1 1.85 (1.41-2.44) 1.97 (1.51-2.62)
25,182 3.1 3.01 (2.12-4.28) 3.25 (2.28-4.63)
19,345 3.2 1.65 (1.65-2.45) 1.72 (1.16-2.57)
37,019 2.3 1.98 (1.98-2.62) 2.12 (1.48-3.03)
7,508 7.2 1.79 (1.79-2.74) 1.89 (1.23-2.91)
2,282 3.5 1.32 (0.50-3.52) 1.38 (0.50-3.77)
42,245 3.1 1.91 (1.44-2.54) 2.05 (1.54-2.74)
21,272 3.9 2.03 (1.42-2.91) 2.14 (1.50-3.07)
23,225 2.5 1.67 (1.09-2.54) 1.78 (1.16-2.73)
11,240 2.4 1.34 (0.78-2.34) 1.60 (0.92-2.82)
33,287 3.4 2.04 (1.49-2.80) 2.13 (1.55-2.93)
rd model adjusting for insurance type, anti-diabetic medications at baseline, use
ta blockers, calcium channel blockers and thiazide diuretics during follow-up.
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nificantly increased mortality in the diabetic patients with-
out cardiovascular disease. However, aspirin tended to
decrease mortality among elderly diabetic patients with
cardiovascular disease. Recently, Sacco et al. [24] per-
formed prospective multicenter study, the use of low-dose
aspirin was ineffective in primary prevention of major ad-
verse cardiovascular events for patients with nephropathy
(HR: 1.11 95% CI 0.91-1.35). On the other hand, the Fre-
mantle Diabetes Study (FDS) [25] showed that regular as-
pirin use was independently associated with reduced
cardiovascular disease mortality (HR 0.30, 95% CI; 0.09-
0.95) and all-cause mortality (HR 0.53, 95% CI; 0.28-0.98)
among the 651 low-dose aspirin users (7.7%) without prior
cardiovascular disease. There was a possibility of selection
bias in recruiting the FDS study participants: 1,426 were
recruited to the cohort voluntarily among the postal code-
defined urban community-dwellers with diabetes (2,258
patients). Previous studies provided explanations for the
failure (non-responsiveness, resistance) of aspirin in the
primary prevention of diabetic patients [15-18,22,23].
This study had several strengths. The study reflects the
real world situation among a nationwide representative
population, which covered all diabetic patients using the
national health insurance claims database in Korea. For
reducing bias due to confounding by indication, we re-
stricted study subjects to those who were without any
diagnosis or medications history of cardiovascular disease
[26], and we applied advanced statistical methods like pro-
pensity score [12]. We identified potential confounding
factors including pre-existing medical conditions and use
of medication in the year prior to the index date. We in-
cluded the insulin or oral hypoglycemic use as a proxy in-
dicator for the severity of diabetes, and the presence of
COPD as a proxy for the smoking. We also comprehen-
sively considered widely used medications in relatively re-
cent years such as statin and anti-hypertensives. The
HIRA database is a valuable data source for epidemiologic
research; the overall positive predictive value of the diag-
nosis was about 70% [27]. Diagnosis of severe condition
such as ischemic stroke was reported to be higher accur-
acy for claims compared with those of other mild condi-
tions [28]. In particular, diagnosis of diabetes (ICD-10
codes E10–14) in HIRA database was reported to have a
positive predictive value of 72.3% in outpatients and 87.2%
in inpatients compared to the clinical information ob-
tained by using hospital medical records [29]. We consid-
ered both diagnosis and prescription to guarantee a more
accurate definition of diabetic patients.
However, these results must be interpreted in light of
some potential limitations. One is that despite applying
advanced statistical methods like propensity score
matching to reduce the effect of confounding, it could
not completely rule out bias such as confounding byindications and unmeasured confounders. We could not
consider variables that were not included in the claims
database such as obesity, smoking, alcohol consumption,
or use of over-the-counter drugs. Aspirin is available as an
over-the-counter drug and prescription drug in South
Korea. We assumed that most patients with diabetes re-
ceived low-dose aspirin with a prescription during regular
clinical visits for managing their diabetes because low-
dose aspirin applied to health insurance coverage is dis-
counted compared to over-the-counter self-medication.
Accordingly, very few patients bought aspirin at the drug
store as over-the-counter drug. We identified very low use
of aspirin among the study subjects. Park IB et al. [30] also
reported that significant underuse of aspirin therapy
among the newly diagnosed diabetes in Korea previously.
Current guidelines for managing diabetes mellitus, as-
pirin is no longer recommended for CVD prevention at
low CVD risk considering the balance of benefit and risk
[31]. Based on our results, low-dose aspirin might be not
effective with early-stage of diabetes. However, we did not
follow-up those patients for a long time, therefore, this re-
sults should be interpreted with caution. Up to now, many
retrospective studies have been published. On current
evidence-conflicting stage, clinicians should evaluate the
balance of benefit and risk of low-dose aspirin considering
the prevalence period with diabetes. To confirm this issue,
randomized controlled trial should be performed for gen-
erating strong evidence. Further studies of large-scale
intervention trials [32,33] currently in progress will pro-
vide more confirmation of the role of low-dose aspirin for
the primary prevention of cardiovascular diseases in pa-
tients with diabetes.
Conclusions
In summary, the use of low-dose aspirin was associated
with the development of ischemic stroke in diabetic pa-
tients without cardiovascular diseases after restricting study
subjects and propensity score matching. These results sug-
gested that low-dose aspirin use for the primary prevention
of ischemic stroke should be reconsidered in diabetic
patients.
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